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Cardiovascular disease is most deadly medical condition in the United States.
Medial vascular calcification is a disease that often precedes other more serious
cardiovascular diseases that have high mortality. In order to research new therapies for
the treatment of medial vascular calcification, an in vitro cell culture model must be
developed that mimics the process in vivo. This disease is shown to be an active, cellmediated process where the vascular smooth muscle cells (VSMCs) in the arteries are
differentiating into osteoblast-like cells and depositing hydroxyapatite mineral in the
artery walls. By administering inorganic phosphate to cell culture medium, an osteogenic
shift can initiated in VSMCs in vitro resulting in calcium deposition and an increase in
bone related proteins. We propose to develop and characterize a model for vascular
calcification and investigate the effects of magnesium supplementation on in vitro
calcification and cellular phosphate uptake.
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CHAPTER I
INTRODUCTION

Motivation
Heart disease is the leading cause of death for both men and women in the United
States (1). Every year, over 700,000 Americans suffer from a heart attack (1). In 2008,
over 600,000 people died of cardiac disease related events; this makes up nearly 25% of
all deaths in the United States that year (2). In addition to the death toll, cardiovascular
disease puts a large economic burden on Americans. In 2010, coronary heart disease
alone cost the United States over $100 billion (3). Additionally, the prevalence of
cardiovascular disease is highest in Mississippi, where in 2000, the cardiovascular
mortality rate was 29% higher than the United States as a whole. The risk factors that
most significantly contribute to cardiovascular disease include high blood pressure, high
blood cholesterol, physical inactivity, being overweight/obese, and smoking (4-6). In all
of these risk factor categories, Mississippi ranks near the top in the nation in incidence.
Cardiovascular disease is prevalent issue in our communities today and many lives have
an opportunity to be compacted by advances in cardiovascular research.
Arterial Structure
The cardiovascular system is composed of heart, arteries, veins, and capillaries.
The primary function of this system is to provide oxygen and nutrients to the body while
1

removing waste via the bloodstream. The arteries delivers oxygenated blood to the body
and the venous system returns the blood to the heart and lungs. Systemic arteries are
comprised of 3 distinct layers: the tunica intima, the tunica media, and the tunica externa
(7). The tunica intima is the inner most layer of the artery that is in contact with the blood
and is lined with endothelium. The tunica media is the middle layer of the artery
composed of vascular smooth muscle cells (VSMCs). This layer is responsible giving the
artery the ability to contract via vascular constriction. The tunica externa is the strong,
outer layer of the artery composed of extracellular matrix tissue (ECM), primarily elastin
and collagen. Elastin in a viscoelastic protein structure that allows tissue to return to
normal stretching due to an applied force (8). This property of elastin contributes to
arterial compliance. The arteries aid the heart by providing additional force needed to
supply the body with blood through vascular constriction. This constriction is made
possible through the vascular elasticity due largely in part to the ECM tissue elastin, and
the constricting capabilities of VSMCs (7).
Vascular Calcification
Together, the heart and arteries work together to deliver nutrition to the body.
However, a variety of medical complications can occur in this system, particularly,
vascular calcification. Vascular calcification can occur either at the intimal or medial
layer of the artery (9-11).
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Intimal Vascular Calcification
Intimal vascular calcification, or atherosclerosis, is characterized by plaque buildup in the intimal layer of artery due to low density lipoproteins (LDLs) (11-14). LDLs
cause intimal calcification through aggregation and oxidation in the intimal layer of the
artery (15). The oxidized/modified LDLs stimulate both innate and adaptive
inflammatory response causing endothelial cells and smooth muscle cells to produce
adhesion molecules resulting in the accumulation of white blood cells, cholesterol, and
triglycerides (15). This pathology may remain asymptomatic for years before finally
fulling enclosing the artery or dislodging and blocking blood flow somewhere
downstream; the effects of this can be catastrophic. A dislodged plaque can become
lodged in the coronary artery or brain, producing heart attack or stroke. In order to treat
this, surgeons will often use balloon angioplasty to open the lumen where plaque build-up
was exposing the artery. In turn, physicians routinely apply a stent to the site to prevent
restenosis from occurring.
Medial Vascular Calcification
Medial vascular calcification, or Monckeberg’s arteriosclerosis, is characterized
by hydroxyapatite mineral deposition in the medial layer of the artery walls (16-18),
primarily at sites of degraded elastin (19-21). This mineral deposition results in loss of
arterial elasticity and compliance. This accumulation of bone mineral in the degraded
elastin disrupts the elastic potential of the arteries by preventing the elastin from
exhibiting its natural viscoelastic behavior. Once thought to be a passive process
associated with aging, research is now showing this calcification to be an active, cellmediated process; clinical and in vitro calcification studies have shown that mineral
3

imbalances result in an osteogenic transition of VSMCs to an osteogenic phenotype. This
is a result of the down-regulation of VSMC contractile proteins in conjunction with an
up-regulation of bone matrix proteins. Thus, VSMCs in the medial layer of the artery are
differentiating into osteoblast-like cells and depositing hydroxyapatite mineral in the
artery similarly to bone remodeling (22-25). In bone remodeling, osteoblasts deposit
hydroxyapatite and osteoclasts resorb hydroxyapatite in response to biological cues and
anatomical needs. In addition to loss of vascular elasticity, the phenotypic switch from
VSMC to osteoblast-like cells results in a decrease in constriction potential of these
VSMCs. In response to the loss of arterial elasticity and constriction ability of the medial
layer, the heart must work harder to deliver adequate nutrition to the body. Although
researchers once believed medial vascular calcification to be have a minimal risk of
mortality, evidence is showing a positive correlation between this calcification and fatal
cardiac events such as myocardial infarction and stroke. In addition to patients exposed to
preventable risk factors, medial vascular calcification is seen to be prominent in both the
aging population (26, 27) and people suffering from Chronic Kidney Disease (CKD) (10,
24, 28-32)
Medial Vascular Calcification and CKD
When healthy, the kidneys serve to remove waste in order to maintain an
appropriate equilibrium of water and minerals in the bloodstream. Particularly, the
kidneys functionally regulate sodium, potassium, calcium, inorganic phosphate (Pi),
magnesium, and other important minerals. Kidney disease effectively limits the ability of
the body to regulate its own water and mineral homeostasis. Kidney disease ranges from
stage 1, which is mild and largely asymptomatic, to stage 5, often referred to as End
4

Stage Renal Disease (ESRD). Once a patient reaches stage 5, the kidneys no longer
function and the patient’s only hope for a long life expectancy is with kidney
replacement. Due to the large number of patients waiting to receive a kidney, kidney
replacement surgery is uncommon and generally involves the patients waiting a long time
for an appropriate match. During this time, the patient must undergo dialysis to remove
water and excess waste from the bloodstream. Although this does effectively remove
waste and bring water to equilibrium, the process does not properly process correct
mineral imbalances in the blood.
Clinical evidence supports that patients in ESRD undergoing dialysis are more
susceptible to medial vascular calcification (30, 31). In fact, it is shown that the majority
of patients in ESRD on dialysis will succumb to heart disease before mortality due to the
kidney disease (32). This calcification in initiated due to the lack of mineral homeostasis
in patients undergoing dialysis. Most notably, blood serum is shown to have an increase
in both Pi and calcium and a decrease in magnesium in dialysis conditions (33). In
clinical studies, there is a positive correlation between increased serum Pi levels and
medial vascular calcification in ESRD patients. In a clinical study performed by
Eddington, et al, 1203 CKD patients were observed to determine a correlation between
serum Pi levels and mortality. The found that in CKD patients in stages 3 and 4, higher
serum Pi levels were associated with an increase in mortality (33). Evidence from clinical
and in vitro studies both indicate that an increase in serum Pi and calcium levels both
contribute to medial vascular calcification by inducing and osteogenic differentiation in
the VSMCs (34). In these hyperphosphatemic/hypercalcemic conditions, VSMCs begin
upregulating bone-related proteins such as runt-related transcription factor 2 (RUNX2),
5

bone morphogenic protein-2 (BMP2) and alkaline phosphatase (ALP) (35, 36). In
addition, the VSMCs begin down-regulating VSMC related proteins, specifically smooth
muscle actin, alpha (α-SMA). The altering of these proteins correlates directly with the
osteogenic switch of VSMCs to an osteoblast-like phenotype (22, 37-39).
Pi Induced Medial Vascular Calcification
Hyperphosphatemia, a condition in which serum Pi levels exceed 1.4 mM, is
commonly seen in ESRD patients has a positive correlation with medial vascular
calcification. Although there are many factors to take into consideration when modeling
vascular calcification, evidence from clinical studies, in vitro studies, and in vivo animal
studies indicates that hyperphosphatemia has a high correlation with the phenotypic
switch of vascular smooth muscle cells to osteoblast-like cells. In vitro, elevated Pi
concentrations correlate to an increase in calcium deposition as well as an increase in the
expression of bone markers.
Elevated serum Pi levels affect vascular calcification both indirectly and directly
(40). Indirectly, elevated hyperphosphatemia results in the increase of FGF-32 and
parathyroid hormone (PTH) levels. This results in a decrease in serum Pi by inhibiting Pi
transporters in the kidneys, resulting in renal excretion of Pi in urine (41). In clinical
studies, elevated FGF-23 and PTH levels have a positive correlation vascular
calcification (42). Directly, Pi-induced calcification is due primarily to the sodiumdependent Pit-1 channel and the sodium-dependent co-transporter protein (NaCP);
knockdown of the Pit-1 channel has shown to significantly reduce VSMC calcification
(43). NaCP moves Pi into the cell by binding with hydrogen Pi, with 3 supporting sodium
ions, or dihydrogen Pi with 2 supporting sodium ions. By binding with the Pi and
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sodium, NaCP allows the transport across the membrane via the activated sodiumdependent Pit-1 channel. This channel is activated in response to elevated extracellular
phosphorus concentrations (40, 44). Once inside the cell, Pi interacts with the nucleus and
upregulate osteogenic genes, particularly runt-related transcription factor-2 (RUNX2) and
Alkaline Phosphatase (ALP). The activation of these genes results in the upregulation of
bone-related proteins such as bone morphogenic protein-2 (BMP-2), osteocalcin, and
ALP. Consequently, VSMC related proteins, such as alpha smooth muscle actin (SMAα), and calcification inhibitory proteins such a matrix Gla proteins (MGPs) are
downregulated (45). In response to the upregulated Pi concentrations, matrix vesicles are
packed with Pi and calcium to exit the cell to maintain homeostasis. In a healthy VSMC,
this would be the extent of the mineral deposition. However, the increase in osteogenic
proteins and decrease in calcification inhibitory proteins allows these matrix vesicles to
deposit mineral and act as nucleating sites further calcification.
Research Efforts for the Treatment of Medial Vascular Calcification
While there are currently treatment options for atherosclerosis, such as balloon
angioplasty and stents, treatment options are still medial vascular calcification are
limited. The bulk of clinical trials for the treatment of medial vascular calcification has
been centered on the use of statins. Statins are a class of drug that inhibit HMG-CoA
reductase, an enzyme involved in production of cholesterol. However, the results have
offered very conflicting reports. A recent clinical study by Henein found that high-dose
or long-term statin treatment accelerate coronary artery calcium levels but this was not
associated with a greater risk of cardiovascular events (46). Additionally, a clinical study
by Taylor, et al, showed statins actually reduce the rate of cardiovascular mortality (47).
7

In contrast, a study performed by Mohrschladt, et al, saw no decrease in the risk of
cardiovascular mortality when patients were treated with statins (48). Aside from statins,
despite the benefit that balloon angioplasty and stents have with opening the arterial
lumen, they do not do anything to reverse medial matrix mineralization. To accommodate
for this, many researchers our developing new treatment options to inhibit or reverse this
medial vascular calcification
Our research group is currently researching a variety of treatment options for this
disease. It has been hypothesized that the delivery of osteoclasts to sites of calcification
could be a potential treatment option (23, 25, 49). Using this technique, osteoclasts would
resorb hydroxyapatite mineral in the arteries much like they would in bone remodeling.
In bone remodeling, osteoblasts deposit hydroxyapatite mineral and osteoclasts resorb
hydroxyapatite mineral based on physiological and anatomical needs. Previous research
has already shown that osteoclasts have the ability to demineralize calcified elastin in
vivo (50). However, in order for this technique to work, a delivery vehicle for osteoclast
delivery must be developed. This vehicle must protect the cells from the mechanical
stress endured during site delivery, be physiologically inert, be small enough to fit inside
the walls of the artery, and have the ability to release the cells at sites of calcification with
high viability.
Other treatment options being researched involve the administration of a protein
or drug at sites of calcification to inhibit or reverse the mineralization. Specifically,
Fetuin-A has been explored as a potential option. Fetuin-A is an inflammatory responserelated calcium regulatory glycoprotein and acts as a calcification inhibitor by binding to
excess calcium in serum (51-53). ESRD and non-renal patients with lowered serum
8

Fetuin-A levels are shown to be more susceptible to medial vascular calcification in
clinical studies (54-56). Vitamin K has also been researched as a potential treatment for
vascular calcification. Vitamin K inhibits calcification through the activation of (MGPs),
an inhibitory protein for calcification. In healthy VSMCs, MGPs actively inhibit
calcification from occurring. However, during the osteogenic shift of VSMCs to
osteoblast-like cells, the expression of MGPs is down-regulated. In contrast, MGPs are
vitamin K dependent and an increase in vitamin K has shown to result in an increase in
MGP activation (57-59). By increasing MGP activation, vitamin K has shown to be an
effective calcification inhibitor in both clinical observation studies and in vitro cell
culture studies (60, 61).
Recently, magnesium is being researched as potential treatment option for this
mineralization. Clinical studies have shown that ESRD patients have decreased serum
magnesium levels when undergoing dialysis in conjunction with elevated serum Pi and
calcium levels (62, 63). Magnesium, a known Pi binder, is believed to play some role in
the Pi-induced vascular calcification. It is believed that at normal serum levels,
magnesium binds to excess Pi to inhibit calcification (64). It is hypothesized that by
elevating serum magnesium levels back to a physiologically normal range, or higher,
medial vascular calcification can be inhibited or even reversed. Several clinical studies
have shown a decrease in cardiovascular mortality in CKD patients that did not have
reduced serum magnesium levels (64-66). One in vitro study performed by Kircelli, et al,
confirmed the inhibitory effect of magnesium after 14 days when increasing magnesium
concentration in cell culture medium to 3.0 mM (67). However, the exact process in
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which magnesium inhibits calcification is not very well understood and it is not clear
whether magnesium can reverse the effects of calcification (68).
Project Outline
Research Hypothesis
Medial vascular calcification is a serious complication that can lead to morbidity
is a variety of ways. By decreasing vascular compliance, the heart is subjected to a more
intense workload, characterized by increased hypertension, which leads to more serious
cardiovascular pathologies. Directly, medial vascular calcification can limit blood supply
vital organs causing disruptive effects. It is necessary for additional research to be done
on medial vascular calcification in order to begin developing therapies to combat the
disease.
In order for our group to effectively perform research experiments of vascular
calcification, an in vitro model must be developed that accurately simulates medial layer
mineral deposition. This model must use VSMCs and involve differentiation of the
VSMCs into osteoblast-like cells using mechanisms seen in the body. An osteogenic
switch can be induced in VSMCs by increasing Pi levels in cell culture media much like
blood serum levels in CKD patients (30, 69, 70). Once a model is confirmed, a new
method to inhibit calcification can be observed. We are proposing a calcification model
and potential treatment with these specific aims:

10

Specific Aims
Aim 1: Develop and characterize an in vitro model for vascular calcification.
Aim 2: Examine the inhibitory and reversal effects of magnesium supplementation on
VSMC calcification.

11

CHAPTER II
AIM I: DEVELOPMENT OF A MODEL FOR VASCULAR CALCIFICATION

Introduction
In Vitro Vascular Smooth Muscle Cell Calcification
Previously reported literature has shown that calcification can be induced in vitro
by administering osteogenic agents to cell culture medium. These agents typically include
Pi, ascorbic acid, dexamethasone, or some combination of these agents (69-76). As
previously described, clinical studies show that CKD patients with high serum Pi levels
are more susceptible to medial vascular calcification. In vitro, Pi levels comparable to
those seen in hyperphosphatemic individuals (patients with a serum Pi level greater than
1.45 mM) induces VSMC calcification and promotes an osteogenic phenotype in VSMCs
(71, 77) . Previously reported literature has shown in vitro VSMC calcification to be time
and dose dependent in Pi concentrations increasing from 1.4 mM to 3.0 mM (70, 78). In a
study performed by Ciceri, et al, Pi levels were increased from 0.0 mM to 5.0 mM. The
group recorded an increased in cellular calcium deposition in correlation with an increase
in Pi concentrations (79). Additionally, Giachelli, et al, observed the same dosedependent behavior of Pi on cellular calcification when increasing Pi levels from 1.4 to
2.0 mM (69). Using 3.0 mM Pi concentrations allows for the most quantifiable calcium
deposition at 14 days while still remaining in a physiologically acceptable range for those
who are hyperphosphatemic.
12

An increase in extracellular phosphorus results in an increase in cellular Pi uptake
through the sodium-dependent Pit-1 cotransporter (43, 44, 80). The increase in
intracellular Pi levels causes an up-regulation of osteogenic genes in the nucleus
including RunX2, BMP-2 and Alkaline Phosphatase (ALP) (81-84). This genetic increase
results in an increase in osteoblast-related proteins within the cell. In response to the
elevated intracellular calcium levels, matrix vesicles are loaded with Pi and calcium to
exit the cell (85). In a non-osteogenic environment, calcification inhibitors prevent these
matrix vesicles from further mineralizing outside the cell (85). However, with the
osteogenic shift of the VSMCs, expression of calcification inhibitory proteins, such as
MGPs, are lost (86, 87) . This causes matrix vesicles to serve as nucleating sites for
hydroxyapatite accumulation in the high Pi environment. That being said, by increasing
Pi levels in cell culture medium, medial vascular calcification can be effectively modeled
to mimic in vivo conditions.
Replicative Senescence in Vascular Smooth Muscle Cells
Along with CKD patients, medial vascular calcification is increasingly prevalent
in the aging population. In previous literature, inducing replicative senescence, a
condition in which normal cells enter a state of irreversible growth inhibition after a
specific number of replications/passages, is used in vitro method to simulate the aging
process (88-91). Physiologically, senescence is due to telomere shortening, oncogene
activation, irradiation, irradiation, DNA damage, oxidative stress, viral infections, and/or
toxins, all of which increase throughout aging (92). By expanding and passaging cells
repeatedly, primary cells will eventually stop replicating once they reach senescence. In
vivo, this is believed to be a tumor suppressive mechanism and another underlying cause
13

of aging. In the young population, senescence works to the advantage of the person by
removing genetically unstable cells from the tissue. However, during the aging process,
the rate of cellular senescence is increased, preventing the body from replacing these
unhealthy cells (92). To investigate the effects of cellular senescence on in vitro vascular
calcification, Nakano-Kurimoto, et al, expanded VSMCs to senescence (passage 11 and
passage 13 cells used) and compared the in vitro calcification with low passage VSMCs
expanded to passage 6; in the senescent cells, some groups reached as high as passage 13
(89). They found that the VSMCs that were expanded to senescence showed greater
susceptibility to osteogenic differentiation and calcium deposition. Senescent cells
showed significantly higher calcium deposition compared to passage 6 cells when treated
with 2.5 mM Pi for 7 days. In addition, gene expression of ALP and Type I collagen,
both bone related, was significantly increased in senescent cells (89). However, despite
this research, it is unclear what the effect of near-senescent cells at high passage has on
the osteogenic potential of VSMCs.
Aim I Specific Objectives
Medial vascular calcification is a cardiovascular disorder that serves as a
precursor to many more serious cardiovascular complications. Despite treatment options
being available for atherosclerosis, including stents and balloon angioplasty, therapies for
medial calcification need to be further developed. However, our research group is
currently developing new treatment options. In order to effectively begin researching
potential therapies for vascular calcification, it is first necessary to develop an in vitro
model for vascular calcification. By developing this model, we will be able to test
potential therapies as well as further investigate the cellular mechanisms that govern
14

cellular calcification. Pi is widely used in cell culture to induce an osteogenic shift in
VSMCs. However, in these studies, the Pi source varies between research groups.
Commonly used Pi sources include monobasic sodium phosphate, dibasic sodium
phosphate, β-glycerophosphate, and potassium phosphate (40, 44, 75, 93). For our
purpose, we want to induce calcification in VSMCs by administering 3.0 mM Pi from the
4 previously mentioned sources and determine which source produces the most
significance calcium. Once a Pi source has been determined, we will confirm the
effectiveness of the model by repeating the study and introducing further analytical
techniques. After repeating the study, the model will be tested using high and low
passage VSMCs as variables in order to determine the effect of high passage, nonsenescent cells on in vitro calcification.
Materials/Methods
Cell Culture/Induction of Calcification
Determination of Pi Source
Human Primary Aortic VSMCs (ATCC, Manassas, VA) were purchased and
expanded to passage 3 in standard growth medium consisting of Dulbecco’s Modified
Essential Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1%
penicillin/streptomycin. Cell morphology was visualized using light microscopy. Once
confluent, cells were passaged and seeded at passage 4 in 6-well cell culture plates. Once
cells reached 80% confluency, calcification was induced with 3.0 mM Pi from the
following sources: monobasic sodium phosphate, dibasic sodium phosphate, βglycerophosphate or potassium phosphate (n=4 for each group); this was designated as
15

day 0. Cells were calcified for 1, 3, 7, and 14 days before being analyzed for calcium
content. Cells were fed medium every 2 to 3 days until appropriate time point.
Confirmation of Pi Source
Human VSMCs were expanded in growth medium and seeded at passage 4. For
SEM, cells were plated on cell culture treated coverslips (n=2 for each group). Once cells
reached 80% confluence, calcification was initiated by supplementing growth medium
with 3.0 mM Pi from either monobasic or dibasic sodium phosphate (n=4). After 7 and
14 days, cell cultures were analyzed for calcium content and intracellular Pi content,
while cover slips were processed for SEM imaging. Cells were fed medium every 2-3
days until time points were reached.
Effect of Passage on In Vitro VSMC Calcification
Human VSMCs were expanded in growth medium and seeded at passage 5 and
passage 10. For SEM, cells were plated on cell culture treated cover slips (n=2 for each
group). Once cells reached 80% confluence, calcification was initiated by supplementing
growth medium with 3.0 mM Pi from dibasic sodium phosphate. After 7 and 14 days, cell
cultures were analyzed for calcium content and intracellular Pi content, while cover slips
were processed for SEM Imaging. Cells were fed medium every 2-3 days.
Quantification of Calcium Content
After appropriate time points, cell cultures were rinsed 3 times in phosphate
buffered saline (PBS). Following rinsing, cells were decalcified in 5 ml of 0.6 N HCl for
24 hours in fume hood. After 24 hours, HCl supernatants were collected and the cell
layer was solubilized in 1 ml of 0.1 N NaOH/0.1% SDS. To process the HCl supernatants
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for atomic absorption spectroscopy, sample volume was brought to 7 ml with a 15%
nitric acid and 3000 ppm potassium content via potassium chloride; potassium is added to
prevent chelation of calcium ions. Atomic Absorption Spectroscopy was performed using
a Shimadzu AA-7000. Calcium content of the cell layers was normalized to protein
concentration using BCA Protein Assay Kit (Pierce, Waltham, MA).
Scanning Electron Microscopy
Following treatment, cell cultures grown on cover slips were fixed with ½
Karnovsky’s fixative in 0.1 M sodium cacodylate buffer. Following overnight fixation,
samples were rinsed 4 times with distilled water and post-fixed in 2% OsO4. After postfixation, cell culture samples underwent serial drying by incrementally increasing ethanol
and Hexamethyldisilazane (HMDS) in subsequent rinses. Imaging was performed using a
Zeiss EVO 50 scanning electron microscope at 10 kV. EDS was used to quantify
elemental composition at sites of interest using a Bruker EDS System. Elemental maps
were generated to show spatial distribution of calcium and phosphorus using the Bruker
EDS System as well.
Alkaline Phosphatase Activity
Alkaline phosphatase (ALP) activity was determined after 7 and 14 days of Pi
treatment in passage 5 and passage 10 cell lysates supernatants using a Colorimetric
Alkaline Phosphatase Assay Kit (Abcam, Cambridge, MA). Absorbance of p-nitrophneyl
phosphate (pNPP) was read at 405 nm wavelength on a μQuant Plate Reader system.
ALP activity was normalized to intracellular protein using a BCA Protein Assay (Pierce,
Waltham, MA).
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Intracellular Pi Content Analysis
Intracellular Pi levels were determined after 7 and 14 days of Pi treatment in
passage 5 and passage 10 cells using a Colormetric Phosphate Assay Kit (Abcam,
Cambridge, MA) on cell lysates. Malachite green and ammonium molybdate formed a
chromogenic complex with Pi ions and was read at 650 nm wavelength using a μQuant
Plate Reader system. Pi concentrations were normalized to protein concentrations using a
BCA Protein Assay (Pierce, Waltham, MA).
Statistical Analysis
Statistical significance was determined using one-way Analysis of Variance
(ANOVA) and post-hoc Tukey’s Honestly Significant Difference (HSD) at the α=0.05
significance level.
Results
Initially, Atomic Absorption Spectroscopy was used to determine the amount of
calcium deposited in vitro by cell cultures exposed to monobasic sodium phosphate,
monobasic sodium phosphate, β-glycerophosphate, and potassium phosphate. Calcium
content was determined quantitatively by comparing absorbance values of samples with
the plot generated by standards. Control cells receiving only growth medium show no
significant increase in calcium content at any time point. In contrast, all groups treated
with Pi show a significant increase in calcium deposition after 14 days. Both monobasic
and dibasic sodium phosphate show a significant increase in calcium deposition after 7
and 14 days compared to control cells. Monobasic and dibasic sodium phosphate also
produced significantly more calcium deposition at 7 and 14 days than cell cultures treated
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with β-glycerophosphate and potassium phosphate. Calcium deposition from monobasic
and dibasic sodium phosphate was not significantly different from each other. However,
less variation at 14 days was seen in the cultures treated with dibasic sodium phosphate,
Figure 1.

Figure 1

Calcium content of human vascular smooth muscle treated with either
monobasic sodium phosphate, dibasic sodium phosphate, βglycerophosphate, or potassium phosphate for 1,3,7, and 14 days.

(* p<0.05)
After calcium content from the initial Pi source study was determined, the
repeatability of the chosen Pi source was verified by using atomic absorption
spectroscopy to measure calcium deposition of cultures after 7 and 14 day treatments
with 3.0 mM Pi from monobasic and dibasic sodium phosphate. After 7 and 14 days, both
monobasic and dibasic sodium phosphate supplementation produced a significant
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increase in calcium deposition compared to control cells treated with only growth
medium. No significant increase in calcium deposition was seen in control cells between
7 and 14 days, Figure 2

Figure 2

Calcium content of human vascular smooth muscle after being treated
with either monobasic or dibasic sodium phosphate (*p < 0.05 compared
to 7 day of same treatment, # p<0.05 compared to control of same time
point).

In addition, Phosphate Assay was performed on cell lysates of cells treated with
monobasic and dibasic sodium phosphate to determine intracellular Pi levels after 7 and
14 days. Phosphate Assay Kit is a kit designed to determine Pi levels in samples. The kit
uses malachite green and ammonium molybdate to form chromogenic complex with Pi
ions to produce a colorimetric reaction to be read by an absorbance reader. Both
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monobasic and dibasic treated cell showed a significant increase in intracellular Pi
compared to controls. Also, intracellular Pi levels of cells treated with Pi were
significantly higher at 14 days than 7 days. No significant difference was seen between
monobasic and dibasic treated cells at either time point, Figure 3.

Figure 3

Intracellular Pi content of human vascular smooth muscle after being
treated with either monobasic or dibasic sodium phosphate (#p < 0.05
compared to 7 day time point of same treatment, * p<0.05 compared to
controls of same time point).

To further analyze the model, scanning electron microscopy was used to visualize
mineral deposition in cells treated with monobasic and dibasic sodium phosphate after 7
and 14 days. Images were taken at 5000x magnification, Figure 4. Cells treated with only
growth medium with showed normal cellular morphology, free of calcium deposition, at
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both time points; EDS detected no calcium at sites of interest in control cells. In contrast,
apparent mineral deposition was imaged and verified to have calcium present in cells
treated with monobasic and dibasic sodium phosphate at both 7 and 14 days.
Additionally, EDS values of at the sites of interest in depicted by the arrows in Figure 4
can be seen in Table 1.
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Figure 4

Scanning electron microscopy of control and calcified human vascular
smooth muscle cells after 7 and 14 days of treatment with monobasic and
dibasic sodium phosphate

Image A is of human vascular smooth muscle cells that received only growth medium for 7 days in culture; the point
indicated by the arrow had no calcium present when analyzed by EDS. Image B is of human vascular smooth muscle
cells calcified for 7 days with monobasic sodium phosphate; the point indicated by the arrow was shown to be 14.73%
calcium by weight. Image C is of human vascular smooth muscle cells calcified for 7 days with dibasic sodium
phosphate; the point denoted by the arrow was shown to be 10.33% calcium by weight. Image D is of human vascular
smooth muscle cells that received only growth medium for 14 days; the point denoted by the arrow had no calcium
present when analyzed by EDS. Image E is of human vascular smooth muscle cells calcified for 14 days with
monobasic sodium phosphate. The point denoted by the arrow was shown to be 20.69% calcium by weight. Image F is
of human vascular smooth muscle cells calcified for 14 days with dibasic sodium phosphate; the point denoted by
arrow was shown to be 12.73%. Images were taken at 5000x magnification, scale bar = 2 μm.
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Table 1

Elemental content of cells treated with monobasic and dibasic sodium
phosphate for 7 and 14 days

Sample
% Carbon
% Oxygen
% Calcium
% Nitrogen
7 Day Control
69.76
14.64
0
15.68
7 Day Monobasic
49.75
35.53
14.73
0
7 Day Dibasic
61.23
28.44
10.33
0
14 Day Control
84.14
15.86
0
0
14 Day Monobasic
45.11
34.19
20.69
0
14 Day Dibasic
79.15
8.12
12.73
0
Results reports as percent, by weight
EDS analysis showed the above elemental contents of the sites of interests depicted by
arrows in the SEM images, Figure 4
Elemental mapping was performed on VSMCs subjected to 3.0 mM Pi from
either monobasic or dibasic sodium phosphate for 7 and 14 days to observe spatial
distribution of carbon (green), calcium (red) or phosphorus (blue) in cell cultures. In
control cells at both time points, a uniform distribution of carbon, calcium, and
phosphorus can be seen without any aggregation. In contrast, cells treated with either
monobasic or sodium phosphate see a significant aggregation of calcium at sites of
suspected hydroxyapatite mineral deposition as noted by red in the elemental maps.
Phosphorus, on the other hand, was more uniformly distributed amongst calcified cells.
Despite this, there are still areas that are clearly rich in phosphorus. Maps were generated
at 5000x magnification, Figures 5-10.
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Figure 5

Elemental map of human vascular smooth muscle cells treated with
standard growth medium or 7 days.

Image A is bright field image of human vascular smooth muscle cells that received only
growth medium for 7 Days in culture. In image B, a fairly uniform distribution of carbon,
calcium, and phosphorus can be seen. As depicted in image C, calcium is uniformly
distributed amongst the culture without aggregation. Like calcium, image D shows a
uniform distribution of phosphorus in the cell culture without aggregation. Images taken
at 5000x magnification, scale bar = 9 μm.
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Figure 6

Elemental map of human vascular smooth muscle cells treated with
monobasic sodium phosphate for 7 days.

Image A is bright field image of human vascular smooth muscle cells that received only
growth medium supplemented with monobasic sodium phosphate for 7 days. In image B,
concentration of calcium and phosphorus can be seen depicted by the purple color within
the circle. In image C, calcium can be seen uniformly distributed among the culture with
a slight accumulation of calcium seen depicted by the circle. Likewise, image D shows a
uniform distribution of phosphorus in the cell culture with a slight accumulation of
phosphorus seen at the suspected mineral deposition. Images taken at 5000x
magnification, scale bar = 9 μm.
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Figure 7

Elemental map of human vascular smooth muscle cells treated with
dibasic sodium phosphate for 7 days.

Image A is bright field image of human vascular smooth muscle cells that received only
growth medium supplemented with dibasic sodium phosphate for 7 days. In image B,
concentration of calcium and phosphorus can be seen depicted by the purple color within
the circle. It is important to note, however, that the purple color not at the suspected
mineral deposit is largely due to the lack of carbon at those regions and not due to
calcium/phosphorus accumulation. In image C, calcium can be seen uniformly distributed
among the culture with a slight accumulation of calcium seen depicted by the circle.
Likewise, image D shows a uniform distribution of phosphorus in the cell culture with a
slight accumulation of phosphorus seen at the suspected mineral deposition. Images taken
at 5000x magnification, scale bar = 9 μm.
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Figure 8

Elemental map of human vascular smooth muscle cells treated with
standard growth medium for 14 days.

Image A is bright field image of human vascular smooth muscle cells that received only
growth medium 14 days. In image B, a fairly uniform distribution of carbon, calcium, and
phosphorus can be seen. As depicted in image C, calcium is uniformly distributed
amongst the culture without aggregation. Like calcium, image D shows a uniform
distribution of phosphorus in the cell culture without aggregation. Images taken at 5000x
magnification, scale bar = 9 μm.
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Figure 9

Elemental map of human vascular smooth muscle cells treated with
monobasic sodium phosphate for 14 days.

Image A is bright field image of human vascular smooth muscle cells that received
growth medium supplemented with monobasic sodium phosphate for 14 days. Image B
shows a clearly defined region of calcium and phosphorus shown by the rich purple color
of the suspected mineral deposit. In image C, calcium is not uniformly distributed
amongst the culture and is heavily concentrated at the suspected mineral deposit.
Likewise, image D shows a heavily concentrated region of phosphorus deposition that
matches the calcium accumulation seen in image C. Images taken at 5000x
magnification, scale bar = 9 μm.
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Figure 10

Elemental map of human vascular smooth muscle cells treated with
dibasic sodium phosphate for 14 days.

Image A is bright field image of human vascular smooth muscle cells that received
growth medium supplemented with dibasic sodium phosphate for 14 days. Image B
shows a clearly defined region of calcium and phosphorus shown by the rich purple color
of the suspected mineral deposit. In image C, calcium is not uniformly distributed
amongst the culture and is heavily concentrated at the suspected mineral deposit. In
contrast, image D shows a uniform distribution of calcium throughout the culture and an
accumulation at the site of heavily concentrated calcium in image C. Images taken at
5000x magnification, scale bar = 9 μm.
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Following confirmation and further analysis of the model, the effect of passage on
the model was observed. Calcium content of passage 5 and passage 10 cells calcified
with dibasic sodium phosphate was analyzed using atomic absorption spectroscopy. After
7 days, passage 5 cells treated with 3.0 mM Pi produced significantly higher calcium
deposition than control cells of the same passage. Also, passage 10 cells produced
significantly higher calcium deposition than passage 5 cells after 7 days regardless of if
they were treated with Pi or not. After 14 days, both passage 5 and passage 10 cells
treated with 3.0 mM Pi produced significantly higher calcium deposition than control
cells of the same passage. Whereas, with passage 10 cells, a significant difference was
only seen at 14 days between control and calcified cells. Additionally, passage 10 cells
produced significantly higher calcium deposition than passage 5 cells in both control and
calcified conditions. Interestingly, there was no significant difference between passage 10
control cells and passage 5 calcified cells at 14 days. These results support previous
literature that showed that cellular senescence increased calcification in cells treated with
Pi. However, these results also suggest that high passage alone is enough to produce
significant calcium deposition in cell cultures, Figure 11.
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Figure 11

Calcium content of passage 5 and passage 10 cell cultures treated with or
without Pi for 7 and 14 days

Significance is indicated by an asterisk or pound sign (* = p<0.05 comparing calcified
and control cells in same passage cells at the same time point. # = p<0.05 in cultures of
different passage undergoing the same treatment and time point).

To determine the osteogenic potential of the high and low passage cell cultures,
Alkaline Phosphatase Assay Kit was performed to measure ALP activity. ALP is a
protein commonly expressed by osteoblasts. As seen in Figure 12, ALP activity was
significantly increased in high passage cells in comparison to low passage cells.
Unexpectedly, there was no significant increase in ALP activity in cells that were treated
with Pi at either time point. These results, like the atomic absorption results, suggest that
passage number can direct the differentiation of VSMCs into osteoblast-like cells.
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Figure 12

Alkaline phosphatase activity in human vascular smooth muscle cells
treated with Pi for 7 and 14 days at passage 5 and passage 10.

Significance is indicated by asterisk (*=p<0.05 comparing passage 10 cells with passage
5 cells undergoing same treatment).

Administering passage as a variable in the model had an interesting effect on
intracellular Pi uptake. Intracellular Pi content of cell lysates was measured using
Phosphate Assay Kit as previously described. Phosphate Assay Kit is a kit designed to
determine Pi levels in samples. The kit uses malachite green and ammonium molybdate
to form chromogenic complex with Pi ions to produce a colorimetric reaction to be read
by an absorbance reader. As seen in Figure 13, at both 7 and 14 days, treating either
passage 5 or passage 10 cells with Pi resulted in a significant increase in intracellular Pi
levels. At 7 days, passage 10 calcified cells had a higher intracellular Pi level than
passage 5 cells that were calcified. At 14 days, both passage 10 control cells and passage
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10 cells treated with Pi had a significant increase in intracellular Pi levels compared to
passage 5 control cells and passage 5 cells treated with Pi respectively. Interestingly,
there was no significant difference between passage 10 control cells compared to passage
5 cells treated with Pi. These results suggest that the high passage cells have a more
effective means of Pi uptake, even without elevated Pi levels. These results correspond
well with the atomic absorption and ALP values previously described.

Figure 13

Intracellular Pi levels of human vascular smooth muscle cells treated with
Pi for 7 and 14 days at passage 5 and passage 10.

Significance is indicated by an asterisk or pound sign (*=p<0.05 comparing calcified
groups to control groups of same passage and time point, #=p<0.05 comparing passage
10 cells with passage 5 cells undergoing same treatment).
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Scanning electron microscopy was used to visualize mineral deposition in cells
treated with dibasic sodium phosphate at passage 5 and passage 10 at 7 and 14 days.
Images were taken at 5000x magnification and can be seen in Figures 14-15 below. Cells
treated with growth medium with showed normal cellular morphology, free of calcium
deposition, at both time points; EDS detected no calcium at sites of interest in control
cells. Apparent mineral deposition was visible in both passage 5 and passage 10 cells
treated with dibasic sodium phosphate at 7 and 14 days. Although the samples were
visually similar to the previous SEM study, EDS was unable to detect any calcium in
suspected mineral deposits in any of the samples.
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Figure 14

Scanning electron microscopy of passage 5 and passage 10 control and
calcified human vascular smooth muscle cells after 7 days of treatment

Image A is of passage 5 human vascular smooth muscle cells that received only growth
medium for 7 days in culture. Image B is of passage 5 human vascular smooth muscle
cells calcified for 7 days with dibasic sodium phosphate. Image C is of passage 10 human
vascular smooth muscle cells that received only growth medium for 7 days. Image D is of
passage 10 human vascular smooth muscle cells calcified for 7 days with dibasic sodium
phosphate. EDS could not confirm the presence of calcium in either image. Images taken
at 5000x magnification, scale bar = 2μm.
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Figure 15

Scanning electron microscopy of passage 5 and passage 10 healthy and
calcified human vascular smooth muscle cells after 14 days of treatment

Image A is of passage 5 human vascular smooth muscle cells that received only growth
medium for 14 days in culture. Image B is of passage 5 human vascular smooth muscle
cells calcified for 14 days with dibasic sodium phosphate. Image C is of passage 10
human vascular smooth muscle cells that received only growth medium for 14 days.
Image D is of passage 10 human vascular smooth muscle cell calcified for 14 days with
dibasic sodium phosphate. EDS could not confirm the presence of calcium in either
image. Images taken at 5000x magnification, scale bar = 2μm.
Discussion
As expected, it is clear that supplementing growth medium with Pi causes
VSMCs to deposit mineral in vitro as highlighted in previous literature (40, 44, 75, 93), .
When comparing monobasic sodium phosphate, dibasic sodium phosphate, βglycerophosphate, and potassium phosphate, both monobasic and dibasic sodium
phosphate produced the most significant calcium deposition after 7 and 14 days. We
believe this increase in calcium deposition in sodium phosphates to be due to the
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mechanism in which Pi is taken up by the cell. PIT-1 channels in VSMCs are activated in
a response to an increase in extracellular phosphorus concentrations or an increase in
intracellular calcium levels (44, 80). This channel is responsible for cellular uptake of Pi
and it is a sodium dependent channel (43). By using sodium phosphate as a Pi source,
sodium concentration in the medium is elevated, helping to drive this process more
effectively than other Pi sources.
In order to confirm the effectiveness of sodium phosphates as a Pi source, the
study was repeated using only monobasic sodium phosphate and dibasic sodium
phosphate as Pi sources for 7 and 14 days. When repeating this study, a significant
increase in calcium deposition was observed in cells treated with Pi in comparison to
controls. This significant increase in calcium deposition was expected as previous
literature has reported similar results (78, 80, 94). Additionally, both using both
monobasic and dibasic sodium phosphate resulted in a significant increase in intracellular
Pi levels in a time dependent manner; there was no significant different between cells
treated with monobasic or dibasic sodium phosphate with respect to Pi uptake. A review
paper by Giachelli shows that the Pi transporter activity is necessary for mineralization.
Previous work determined that by blocking the Pit-1 sodium dependent Pi cotransporter
with phosphonoformic acid, a competitive inhibitor of the channel, Pi uptake and calcium
deposition were both down-regulated (69). Thus, intracellular Pi levels must be elevated
in order for matrix mineral deposition to occur. Our intracellular Pi analysis confirmed
that intracellular Pi levels increased along with an increase in cellular calcium deposition.
In order to more effectively characterize our model, SEM and elemental mapping
was performed on cells calcified with monobasic and dibasic sodium phosphate. VSMCs
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treated with only growth medium revealed normal VSMC morphology when viewed
under SEM. Likewise, very few suspected calcium deposits were visible. In contrast,
after 7 days of treatment with monobasic or dibasic sodium phosphate, the cell layer is
inhabited by a number of suspected sites of calcification. Using EDS, we were able to
confirm that these sites did have detectable levels of calcium not seen in control cells.
After 14 days, the suspected calcium nodules were greater in number than cells treated
for 7 days. Once again, EDS was able to confirm that the sites of interest had calcium
present. Typical qualitative imaging of calcification in literature is performed by staining
calcified cultures with alizarin red. Alizarin red binds to calcium deposits in cell cultures,
showing areas of calcification to be very red in color. Previous literature shows that
exposure to osteogenic conditions results in the increased calcium nodule formation
visible through alizarin red staining (95-98). Although not common in literature, using
SEM and EDS allows us to visually observe calcification at a higher resolution and
precision than by using alizarin red staining.
To further investigate the conclusion that these suspected sites truly represent the
hydroxyapatite mineral we want to produce in cell cultures, elemental mapping was done
to observe the spatial distribution of carbon, calcium, and phosphorus in calcified cells
compared to controls. At both 7 and 14 days, cells cultured in standard growth medium
saw a uniform distribution as carbon, calcium, and phosphorus on the surface of the cell
layers. These elements are commonly seen in cells so the results are expected. In contrast,
at 7 days, small accumulations of calcium and phosphorus can be seen in cells treated
with Pi. After 14 days, the accumulation of calcium and phosphorus is clearly apparent in
large suspected mineral deposits. Although elemental mapping had not previously been
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performed on calcified VSMCs, this mapping technique is often used in studies where the
known distribution of multiple elements in cell culture or tissue is desired (99). In a study
performed by Ramos, et al, elemental mapping was used to determine calcium and Pi
distribution in chicken egg yolk (100). By using this mapping technique on calcified cell
cultures, we are able to expand visual analysis to confirm that both calcium and Pi are
present at suspected sites of calcification.
After confirming and characterizing the effectiveness of the model, we chose to
proceed by using dibasic sodium phosphate in future studies due to less variation in
calcium deposition at 14 days compared to monobasic sodium phosphate. Next, the effect
of passage number on the calcification model was observed. A study by NakanoKurimoto reported in increase in calcium deposition by cells treated with Pi that have
reached cellular senescence compared to low passage cells treated with Pi (89). Briefly,
cellular senescence is reached when cells have been passaged/replicated to the point
where they no longer replicate. We wanted to examine the effects of using high passage,
non-senescent cells on the calcification model. Unlike the previous study by NakanoKurimoto that only observed the difference between senescent cells and low passage
cells, all treated with Pi, we also observed the effect of high passage on control cells
treated with only growth medium with regard to calcium deposition. When using passage
10 cells, control and Pi treated, we saw an increase in calcium deposition and intracellular
ALP activity in comparison to low passage cells, Figures 11 and 12. These results suggest
that high passage cells are more susceptible to an osteogenic shift and have the ability to
differentiate to an osteoblast-like phenotype even when extracellular Pi levels are not
increased. These results are similar to previously reported literature, by Minamino and
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Komuro that suggests that the age of cells directly affects the health and phenotype of the
cell. They claim, that telomere length in vascular cells is shortened throughout the life of
the cell that shortening may be related to age-associated vascular diseases (101). That
being said, if telomere shortening is occurring over the life of the VSMC, an osteogenic
transformation of the VSMCs would be expected even if they haven’t fully reached
senescence. Interestingly, intracellular Pi levels of high passage cells were significantly
higher than low passage cells, even in controls. This may suggest that the PIT-1
transporter is activated at a higher rate in high passage cells than low passage cells; it is
expected that an osteoblast-like cell would have a higher Pit-1 activation than VSMCs
(102). Unlike the intracellular Pi analysis performed on VSMCs treated with monobasic
and dibasic sodium phosphate, there was not a significant increase in intracellular Pi
concentration at 14 days in comparison to 7 days. Despite this, the increase in quantified
calcium deposition in high passage cells parallels well with the increase in intracellular Pi
and ALP activity. Unlike the previous study we performed utilizing SEM, the SEM
images did not correspond with the quantitative data. Despite seeing an increase in
calcium deposition in high passage cells, there was no discernable difference between
high passage and low passage cells treated with Pi with regards to visual mineral
deposition. Additionally, no significant degree of mineralization was visually apparent in
passage 10 control cells despite having an increase in quantified calcium deposition.
Also, EDS was unable to detect calcium in any suspected nodule in either control or
calcified cells at high or low passage. This is an unexpected result due to the abundance
of detectable calcium in the previous study. To explain this, it is believed that the
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suspected sites of interest were something other than hydroxyapatite mineral or some
other factor prevented calcium levels from being accurately detected.
To summarize, we have successfully developed a model to simulate medial
vascular calcification in vitro. By supplementing growth medium with 3.0 mM Pi from
dibasic sodium phosphate, we can induce an osteogenic switch in human VSMCs that
results in significant calcium deposition at 7 and 14 days. In addition, this mineral can be
qualitatively observed using SEM and elemental mapping paired with EDS to confirm the
presence of calcium at sites of interest. Finally, unless a model to accommodate for aging
is desired, it is recommended to use cells of a low passage. High passage cells show an
increase in calcium deposition in both control and Pi treated cells. Additionally, high
passage cells show a significant increase intracellular Pi and ALP activity. To more
accurately simulate Pi-induced vascular calcification, it is recommended to proceed with
low passage cells.
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CHAPTER II
EFFECT OF MAGNESIUM SUPPLEMENTATION ON IN VITRO VSMC
CALCIFICATION

Introduction
Background
Magnesium is a mineral element that is found in relatively large amounts in the
body, primarily in bone (103). Magnesium is necessary in over 300 enzymatic reactions
(104). Particularly, magnesium is a known Pi binder and is a crucial mineral in many
cardiovascular and bone related processes (105). Normal magnesium serum levels fall
between 1.5-2.5 mg/dl (0.65-1.09 mM) in healthy patients (106). A patient having less
than 0.75 mM serum magnesium is considered hypomagnesmia. Serious complications
can occur when magnesium is deficient in the blood serum. Magnesium is necessary for
several calcium and Pi related interactions and complications can be as severe as
arrhythmias and sudden death (105). In contrast, a patient having a magnesium serum
level greater than 1.5 mM are considered hypermagnesmia (107). Despite being
hypermagnesmic after surpassing the 1.5 mM serum magnesium concentration, patients
are asymptomatic until serum levels surpass 2.0 mM. Symptoms at this concentration are
typically mild and do not adversely affect the body until serum levels reach 3.0 mM or
greater. Serum levels of magnesium commonly reach 2.5-3.5 mM or higher when used to
treat preemclampsia or eclasmpsia in pregnant women (108). Considering the interactions
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between magnesium and Pi/calcium in the body, researchers have started studying the
relationship between magnesium and medial vascular calcification. It is believed that
magnesium may be serum mineral crucial to inhibit medial vascular calcification.
Clinical Studies with Magnesium
Like many other minerals in the body, CKD patients undergoing dialysis typically
have a significant decrease in serum magnesium levels (66, 109). As previously stated,
CKD patients undergoing dialysis routinely a significant increase in medial vascular
calcification. Since serum magnesium levels are decreased in the same patients that have
an increase in medial calcification, researchers have studied the relationship further. In a
study performed by Sakaguchi et al, 142,069 patients receiving dialysis were observed
for one-year to determine mortality rates (110). They found that patients with elevated
serum Pi levels saw an elevated risk of mortality in patients with normal or below
average serum magnesium levels. However, in patients with serum Pi levels greater than
6.0 mg/dL, cardiovascular mortality risk significantly decreased with increasing serum
magnesium levels. They concluded that serum magnesium levels significantly modified
mortality risk associated with elevated serum Pi levels in patients undergoing
hemodialysis. Thus, researchers observed the effects of magnesium in vitro to determine
if magnesium has an effect on vascular calcification at the cellular level.
Cell Culture Models and Magnesium Supplementation
In order to investigate the effects of magnesium on VSMC calcification in vitro,
Louvet, et al, examined the effects of magnesium supplementation on a cell culture
model for calcification (111). They found that a 2.0 mM concentration of magnesium in
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cell culture media significantly reduced calcium deposition after 14 days of exposure to
high-Pi medium. In addition, cells treated with high-Pi medium alone showed a
significant increase in osteopontin, a bone-related protein. However, these bone protein
levels were comparable to controls when treated with magnesium. Additionally, they
determined that magnesium supplementation positively increased cellular viability
compared to cells treated with Pi alone. In order to ensure this is an active, cell-mediated
process, magnesium was administered to previously calcified, fixed cells; no reduction in
extracellular calcium deposition was seen. These results are promising and suggest that
magnesium can effectively prevent VSMC calcification as an active, cell-mediated
process while also showing an increase in cellular viability in vitro. However, it is still
unsure whether magnesium has the ability to effectively reverse already calcified cells.
Additionally, the exact process in which magnesium works to prevent calcification is
poorly understood and needs to be further investigated.
Research Hypothesis
Based on previous literature, magnesium supplementation can potentially be used
to combat medial vascular calcification. In order to confirm the previously reported
inhibitory effect of magnesium on VSMC calcification in vitro, we wanted to use our
calcification model by supplementing growth medium with 3.0 mM Pi from dibasic
sodium phosphate. To study the inhibitory effect, cell culture magnesium levels will be
raised from 0.117 mM to 2.0 mM starting at day 0 along with the calcification medium.
After 14 days, the effect of magnesium on calcium deposition will be analyzed via atomic
absorption. We expect to see a significant reduction in calcium deposition in cell treated
with magnesium and Pi compared to cells treated with Pi alone.
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In order to determine how effective magnesium is at reversing VSMC
calcification, VSMCs will be calcified with 3.0 mM Pi for 7 days. After calcifying for 7
days without magnesium supplementation, magnesium levels in media will be raised to
2.0 mM in conjunction with continued exposure to calcification medium. After 7
additional days in culture, the effect on calcium deposition will be observed via atomic
absorption. We expect to see calcification inhibited from that point forward along with
potentially seeing a decrease in VSMC calcium deposition.
Despite the known inhibitory effect of magnesium, the process in which this
inhibition occurs is still unclear. Since magnesium is a known Pi binder, we want to
determine if magnesium inhibits calcification by preventing cellular uptake of Pi. By
using Phosphate Assay Kit, intracellular levels of Pi can be observed to determine if
magnesium is a passive, extracellular process or if the magnesium inhibits calcification in
an active, intracellular process.
Specific Aims
Aim 1: Examine the inhibitory and reversal effects on in vitro VSMC calcium deposition
Aim 2: Determine the effect of magnesium supplementation on cellular Pi uptake
Materials/Methods
Cell Culture/Induction of Calcification
Human Primary Aortic VSMC’s (ATCC, Manassas) were purchased and
expanded to passage 5 in Dulbecco’s Modified Essential Medium (DMEM)
supplemented with 10% Fetal Bovine Serum (FBS) and 1% antibiotic
penicillin/streptomycin. Cell morphology was visualized using light microscopy. Once
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confluent, cells were passaged and seeded at passage 6. Once cells reached 80%
confluence, experiment began, designated as day 0. Treatment groups consisted of a 7
and 14 day control receiving only growth medium (n=4), 7 and 14 day calcification group
receiving 3.0 mM Pi from dibasic sodium phosphate (n=4), and 2 magnesium groups.
Magnesium treated groups had cell culture magnesium levels raised to 2.0 mM in
conjunction with 3.0 mM Pi addition. Magnesium supplementation was started at day 0
and after 7 days of calcification (n=4).
Quantification of Calcium Content
After appropriate time points, cell cultures were rinsed 3 times in PBS. Following
rinsing, cells were decalcified in 5 ml of 0.6 N HCl for 24 hours in fume hood. After 24
hours, HCl supernatants were collected and the cell layer was solubilized in 1 ml of 0.1 N
NaOH/0.1% SDS. To process the HCl samples for atomic absorption spectroscopy,
sample volume was brought 7 ml with a 15% nitric acid and 3000 ppm potassium content
via potassium chloride; potassium is added to prevent chelation of calcium ions. Atomic
Absorption Spectroscopy was performed using a Shimadzu AA-7000. Calcium content of
the cell layers was normalized to protein concentration using BCA Protein Assay Kit
(Pierce, Waltham, MA).
Intracellular Pi Content Analysis
Intracellular Pi levels were determined after 7 and 14 days of Pi/magnesium
treatment using a Colorimetric Phosphate Assay Kit (Abcam, Cambridge, MA) on cell
lysates. Malachite green and ammonium molybdate formed a chromogenic complex with
Pi ions and was read at 650 nm wavelength using a μQuant Plate Reader system. Pi
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concentrations were normalized to protein concentrations using a BCA Protein Assay
(Pierce, Waltham, MA).
Statistical Analysis
Statistical significance was determined using one-way Analysis of Variance
(ANOVA) and post-hoc Tukey’s Honestly Significant Difference (HSD) at the α=0.05
significance level.
Results
After 7 and 14 days, calcium content of VSMC cultures treated with Pi and
magnesium was determined and compared to controls receiving only growth medium. As
seen in Figure 16, after 7 and 14 days, cells treated with 3.0 mM Pi produced
significantly higher calcium deposition than control cells receiving only growth medium.
Additionally, cells treated with magnesium at 0 days and at 7 days had significantly
lower calcium deposition compared to cells receiving only growth medium with 3.0 mM
Pi for 14 days.
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Figure 16

Calcium content of human vascular smooth muscle cells treated with Pi
and magnesium

Significance is indicated by asterisk or pound sign (* indicates a p<0.05 comparing
calcified cells to control cells at same time points. # indicates p<0.05 compared to 14 day
calcified group, controls excluded).
After 7 and 14 days, intracellular Pi content of VSMC cultures treated with Pi and
magnesium was determined using Phosphate Assay Kit. As seen in Figure 17, all cultures
treated with Pi (with or without magnesium) had significantly higher intracellular Pi
levels compared to controls receiving only growth medium. Additionally, there was no
significant difference in cells treated with magnesium/Pi compared to Pi alone. This
suggests that magnesium does not affect intracellular uptake of Pi.
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Figure 17

Intracellular Pi content of VSMCs treated with Pi and magnesium.

Magnesium groups received both magnesium and Pi supplementation beginning at
described time point (*p<0.05 compared to control 7 day control, #p<0.05 compared to
14 day control).

Discussion
As seen in literature, a 2.0 mM magnesium concentration in cell culture medium
effectively inhibited VSMC calcification in the presence of Pi similar to the study
performed by Louvet, et al (111) . After 14 days, cell cultures treated with magnesium
and Pi were had significantly lower mineral deposition compared to cultures receiving
only Pi supplementation. Supplementing cell cultures with magnesium after 7 days in
calcifying conditions did not result in a significant reduction in calcium deposition.
However, by administering magnesium/Pi medium after 7 days in calcifying conditions,
further calcium deposition was inhibited. This indicates that magnesium supplementation
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has the ability to halt VSMC calcification in cells that had already been calcified. This
result supports literature by Salem, et al, which believed magnesium supplementation can
be used to treat and limit the further development of medial calcification (64).
Interestingly, magnesium supplementation had no effect on VSMC ability to
uptake Pi. There was no difference in intracellular Pi between cells treated with
magnesium/Pi and Pi only. All groups that were treated with Pi, regardless of magnesium
supplementation, reached comparable levels of intracellular magnesium and were
significantly higher than control cells receiving only growth medium. From this, we can
determine that magnesium does not affect the uptake of Pi through the Pit-1 sodium
dependent cotransporter. In a review reported by Giachelli, VSMC calcification was
inhibited when the Pit-1 cotransporter was blocked using phosphonoformic acid (69). Our
cellular calcification was inhibited in a similar fashion, however, the cells still took up Pi
intracellularly. Since magnesium clearly has an inhibitory effect, the results indicate that
the process in which is works is an active, intracellular process that needs to be studied
further to fully understand. Magnesium is an important mineral involved in many cellular
processes and may serve as a potential treatment option for medial vascular calcification
once the process is more fully understood.
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CHAPTER III
CONCLUSION AND FUTURE WORKS
Conclusion
This study proved the effectiveness of using sodium phosphates as a source to
initiate an osteogenic differentiation in human VSMCs. By supplementing cultures with
3.0 mM Pi, VSMCs deposited significant calcium mineralization in vitro. This was
supported by SEM imaging and elemental mapping that qualitatively showed areas of
calcium and phosphorus deposition in cultures at high magnification. The model begins
to lose its reliability when using cells from a high passage. High passage cells produced
significantly more calcium deposition than low passage cells even in controls.
Additionally, Pi uptake was significantly increased in high passage cells as well as ALP
activity. The results confirm that Pi-induced VSMC calcification is a reliable, static
model to be used in studies when using low passage human VSMC. However, to ensure
the most accurate model, this work needs to be expanded to include additional analysis.
Magnesium proved to have an inhibitory effect on VSMC calcification when
administered to cells at Day 0 and at Day 7 of treatment with cells with osteogenic
medium. However, the ability to effectively reverse calcification was not supported in the
results. However, the role of magnesium is promising since it was able to halt further
calcification in cells that had previously been calcified for 7 days. Also, the magnesium
had no effect on the cells’ ability to uptake Pi. This implies that the mechanism in which
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magnesium works is an active, intracellular process which needs to be studied further in
order to be understood.
Future Works
In order for an in vitro model to increase its validity, it needs to represent in vivo
situations as closely as possible. In order for the calcification model to be a more accurate
predictor in vivo calcification, several modifications and analysis need to be incorporated.
The calcification model itself could be enhanced with the following recommendations:
1. Expand the experimental design to include:
a. Varying concentrations of Pi ranging from 0.8 to 3.0 mM to accommodate
for a wider range of serum Pi levels as seen in patients.
b. Increase calcium concentration in cell culture medium to better mimic the
high serum calcium levels often seen in patients with medial vascular
calcification.
c. Extend the calcification model to past 14 day time points and increase the
number of time points to more accurately understand the calcification
process over time and determine rate of cellular metabolism in the
calcification process.
d. Use western blot analysis to observe osteogenic and VSMC related
proteins and how they change through the calcification process
e. Incorporate collagen, elastin, and endothelial cells into a 3D calcification
model to better represent the structure of a native artery.
f. Develop a 3D, dynamic fluid flow calcification model to understand the
effects of stress and vascular pressure on calcification
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The magnesium study proved that magnesium successfully inhibited calcification.
Also, magnesium showed to have no effect on intracellular Pi uptake. This worked as a
good introductory study which needs to be expanded on in order to understand this
process better. To accommodate this, the following work is recommended:
2. Expand the Magnesium study to include:
a. Varying concentrations of magnesium from 0.8 mM to 2.0 mM
b. Western blot analysis to determine the effect of magnesium on bone and
VSMC related proteins.
c. Extend treatment times for longer than 14 days
d. Determine mechanism of inhibition (think of ideas)
e. Develop a method of magnesium delivery for site-specific treatment

In order for this model to more accurately represent in vivo situations, the
recommendations must be incorporated to account for arterial structure and fluid flow as
seen in native arteries. Additionally, to fully confirm the model, an increase in bone
related proteins needs to be clearly seen in conjunction with a decrease in VSMC specific
proteins. However, the model is promising and can be reliable for future studies
determining effectiveness of treatments.
Magnesium shows great potential in the treatment of medial vascular
calcification. However, in order for magnesium to be an effective treatment, the process
in which it works need to be clearly understood. This involves pinpointing the exact
mechanism in which magnesium inhibits calcification. Additionally, since magnesium is
so commonly used to treat so many pathologies, it is important that magnesium treatment
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be localized to sites of mineral deposition in order to treat medial vascular calcification.
For this to happen, a targeted delivery vehicle must be developed to deliver magnesium
ions specifically to the sites of interest.
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Figure 18

EDS mapping for human vascular smooth muscle cells after 7 days of
treatment with only growth medium

Elemental composition: 69.97% Carbon, 14.64% Oxygen, and 15.68% Nitrogen by
weight

Figure 19

EDS mapping for human vascular smooth muscle cells after 7 days of
treatment with monobasic sodium phosphate

Elemental composition: 49.75% Carbon, 35.53% Oxygen, and 14.73% calcium by weight

68

cps/eV
35

30

25

20
C

O

Ca

Ca
15

10

5

0
1

Figure 20

2

3

4

keV

5

6

7

8

9

EDS mapping for human vascular smooth muscle cells after 7 days of
treatment with dibasic sodium phosphate

Elemental composition: 61.23% Carbon, 28.44% Oxygen, and 10.33% calcium by weight
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EDS mapping for human vascular smooth muscle cells after being treated
with only growth medium for 14 days

Elemental composition: 84.14% Carbon and 15.86% Oxygen by weight
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Figure 22

EDS mapping for human vascular smooth muscle cells after 14 days of
treatment with monobasic sodium phosphate

Elemental composition: 45.11% Carbon, 34.19% Oxygen, and 20.69% Calcium by
weight
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EDS mapping for human vascular smooth muscle cells after 14 days of
treatment with dibasic sodium phosphate

Elemental composition: 79.15% Carbon, 8.12% Oxygen, and 12.73% Calcium by weight
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